Second Neoplasms in Patients With Hodgkin's Disease Following Combined Modality Therapy-The Yale Experience

In the article by Koletsky et al "Second Neoplasms in Patients With Hodgkin's Disease Following Combined Modality Therapy-The Yale Experience" (Journal of Clinical Oncology 4:311-317, 1986), an error was made in the footnote on page 311 which described the composition of MVVPP. The corrected footnote appears below. *MVVPP = nitrogen mustard (0.4 mg/kg on day 1 of cycle); vinblastine (6 mg/m² on days 22, 29, and 36); vincristine (1.4 mg/m², 2 mg maximum dose, on days 1, 8, and 15); procarbazine (100 mg/d on days 22 through 42); prednisone (40 mg/m² on days 1 through 15 for cycles 1, 3, and 5 only).